PMID- 11369902
OWN - NLM
STAT- MEDLINE
DCOM- 20010621
LR  - 20181130
IS  - 0190-9622 (Print)
IS  - 0190-9622 (Linking)
VI  - 44
IP  - 6
DP  - 2001 Jun
TI  - Terbinafine-induced subacute cutaneous lupus erythematosus.
PG  - 925-31
AB  - BACKGROUND: Recently, the induction of subacute cutaneous lupus erythematosus 
      (SCLE) and exacerbation of systemic lupus erythematosus by terbinafine have been 
      reported. OBJECTIVE: We describe 4 cases of SCLE, one associated with chilblain 
      lupus, which occurred during therapy with oral terbinafine for onychomycosis. 
      METHODS: Of 21 consecutive patients with SCLE attending the outpatient 
      dermatology department at Muenster University clinic during a 1-year period, 4 
      patients with terbinafine-induced SCLE were seen. Patients were examined fully 
      and photographed; histologic findings as well as serologic and follow-up data 
      were evaluated. RESULTS: In addition to high titers of antinuclear antibodies 
      (ANA) with a homogeneous pattern, anti-Ro(SS-A) antibodies were present; in 3 of 
      4 women, anti-La(SS-B) antibodies were also found. All patients had anti-histone 
      antibodies as in drug-induced lupus and showed the characteristic genetic 
      association of SCLE with the HLA-B8,DR3 haplotype; moreover, in 2 cases, HLA-DR2 
      was also present. After discontinuation of terbinafine, ANA titers decreased; 
      anti-histone antibodies also became undetectable within 4(1/2) months in 3 
      patients concomitant with subsidence of the SCLE eruption in all patients. 
      CONCLUSION: Terbinafine is a drug that appears to infrequently induce SCLE with 
      high titers of ANAs and anti-histone antibodies in genetically susceptible 
      persons.
FAU - Bonsmann, G
AU  - Bonsmann G
AD  - Department of Dermatology, University of Munster, Germany. 
      bonsmag@uni-muenster.de
FAU - Schiller, M
AU  - Schiller M
FAU - Luger, T A
AU  - Luger TA
FAU - Stander, S
AU  - Stander S
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Antifungal Agents)
RN  - 0 (Histones)
RN  - 0 (Naphthalenes)
RN  - G7RIW8S0XP (Terbinafine)
SB  - IM
MH  - Administration, Oral
MH  - Aged
MH  - Antibodies, Antinuclear/analysis
MH  - Antifungal Agents/*adverse effects/therapeutic use
MH  - Female
MH  - Histones/immunology
MH  - Humans
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/immunology/pathology
MH  - Middle Aged
MH  - Naphthalenes/*adverse effects/therapeutic use
MH  - Onychomycosis/drug therapy
MH  - Terbinafine
EDAT- 2001/05/23 10:00
MHDA- 2001/06/22 10:01
CRDT- 2001/05/23 10:00
PHST- 2001/05/23 10:00 [pubmed]
PHST- 2001/06/22 10:01 [medline]
PHST- 2001/05/23 10:00 [entrez]
AID - S0190-9622(01)34749-7 [pii]
AID - 10.1067/mjd.2001.114565 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2001 Jun;44(6):925-31. doi: 10.1067/mjd.2001.114565.